Rose PG, et al. - Researchers examined clinical prognostic indicators for survival following recurrence of high-grade, advanced-stage ovarian–peritoneal–tubal carcinoma. In addition, they created a nomogram to forecast individual survival following recurrence by retrospectively analyzing 4,739 patients treated in multicenter Gynecologic Oncology Group protocols for stage III and IV ovarian–peritoneal–tubal carcinoma who underwent primary debulking surgery, received chemotherapy with paclitaxel and a platinum compound, and then developed recurrence. Death was reported for the vast majority of patients (89.4%) at a median follow-up of 88.8 months; 21.4 months was the median survival following recurrence. The nomogram was developed using the time to recurrence after initial chemotherapy, clear cell or mucinous histology, performance status, stage IV disease, and age as significant variables. Time to recurrence alone accounted for 85% of the prognostic information indicating its close relation to the estimated survivals after recurrence.